Phytochemical combinations of lichen Evernia prunastri (L.) Ach. reduce drug resistance to temozolomide but not to paclitaxel in vitro.

IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Frontiers in Pharmacology Pub Date : 2025-09-15 eCollection Date: 2025-01-01 DOI:10.3389/fphar.2025.1633978
A Shcherbakova, L Nguyen, A Koptina, A Backlund, S Banerjee, E Romanov, G Ulrich-Merzenich
{"title":"Phytochemical combinations of lichen <i>Evernia prunastri</i> (L.) Ach. reduce drug resistance to temozolomide but not to paclitaxel <i>in vitro</i>.","authors":"A Shcherbakova, L Nguyen, A Koptina, A Backlund, S Banerjee, E Romanov, G Ulrich-Merzenich","doi":"10.3389/fphar.2025.1633978","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Temozolomide (TMZ) and Paclitaxel (PXT), crucial anti-cancer drugs for glioblastoma (GBM) and primary breast cancer (BC), respectively, face drug resistance. Therefore, we investigated the adjuvant potential of characterized extracts of the lichens <i>Evernia prunastri</i> (L.) Ach. (Epr), <i>Cladonia arbuscula</i> (Wallr.) Flot (Car) and their metabolites, evernic acid (EA) and usnic acid (UA) alone or in combination with TMZ and PTX for their immunomodulatory and chemosensitivity increasing potential.</p><p><strong>Methods: </strong>TMZ-resistant U-87 cells, MCF7 BC-cells, and normal human skin fibroblasts (HSKF) were treated with hexane (Hex), dichloromethane (DCM), and acetonitrile (ACN) extracts of Epr (EprDCM, EprACN), Car (CarHex, CarACN), and with EA and UA to measure cell metabolic activity. Molecular mechanisms were predicted using ChemGPS-NP and validated by Western blot, RNA sequencing, quantitative RT-PCR, and Wnt inhibitory factor 1 (WIF1) protein expression. Combinatory effects were calculated by Combination Index (CI) and Zero Interaction Potency methods (ZIP).</p><p><strong>Results: </strong>Extracts and selected metabolites reduced concentration-dependent cellular metabolic activity in U-87 and MCF7 cells. EprACN and EA (U-87 cells: IC<sub>50</sub> 30 μg/mL), safe to HSKF, regulated key proteins in MAP kinases pathways, supporting predictions made by ChemGPS-NP. The combination EA-TMZ showed additive effects (TMZ-reduction: 3.4 fold), reduced transcription of Wnt pathway members, and increased in U-87 cells protein releases of WiF1, the central inhibitor of Wnt-signaling. Further gene expression data (GE) suggest involvement of IL-17 receptor and BDNF.</p><p><strong>Discussion: </strong>The combination EA-TMZ interacts with the Wnt pathway regulation associated with sensitizing U-87 cells, without increasing GEs of pro-inflammatory cytokines. EA deserves further investigation as an adjuvant.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1633978"},"PeriodicalIF":4.8000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477381/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2025.1633978","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Temozolomide (TMZ) and Paclitaxel (PXT), crucial anti-cancer drugs for glioblastoma (GBM) and primary breast cancer (BC), respectively, face drug resistance. Therefore, we investigated the adjuvant potential of characterized extracts of the lichens Evernia prunastri (L.) Ach. (Epr), Cladonia arbuscula (Wallr.) Flot (Car) and their metabolites, evernic acid (EA) and usnic acid (UA) alone or in combination with TMZ and PTX for their immunomodulatory and chemosensitivity increasing potential.

Methods: TMZ-resistant U-87 cells, MCF7 BC-cells, and normal human skin fibroblasts (HSKF) were treated with hexane (Hex), dichloromethane (DCM), and acetonitrile (ACN) extracts of Epr (EprDCM, EprACN), Car (CarHex, CarACN), and with EA and UA to measure cell metabolic activity. Molecular mechanisms were predicted using ChemGPS-NP and validated by Western blot, RNA sequencing, quantitative RT-PCR, and Wnt inhibitory factor 1 (WIF1) protein expression. Combinatory effects were calculated by Combination Index (CI) and Zero Interaction Potency methods (ZIP).

Results: Extracts and selected metabolites reduced concentration-dependent cellular metabolic activity in U-87 and MCF7 cells. EprACN and EA (U-87 cells: IC50 30 μg/mL), safe to HSKF, regulated key proteins in MAP kinases pathways, supporting predictions made by ChemGPS-NP. The combination EA-TMZ showed additive effects (TMZ-reduction: 3.4 fold), reduced transcription of Wnt pathway members, and increased in U-87 cells protein releases of WiF1, the central inhibitor of Wnt-signaling. Further gene expression data (GE) suggest involvement of IL-17 receptor and BDNF.

Discussion: The combination EA-TMZ interacts with the Wnt pathway regulation associated with sensitizing U-87 cells, without increasing GEs of pro-inflammatory cytokines. EA deserves further investigation as an adjuvant.

青苔的植物化学组合研究课时。降低体外对替莫唑胺耐药,但对紫杉醇不耐药。
替莫唑胺(Temozolomide, TMZ)和紫杉醇(Paclitaxel, PXT)分别是治疗胶质母细胞瘤(GBM)和原发性乳腺癌(BC)的关键抗癌药物,它们面临耐药性问题。因此,我们研究了地衣叶青(Evernia prunastri, L.)特征提取物的佐剂潜力。课时。(Epr),丛枝枝(Wallr.)Flot (Car)及其代谢物,evernic acid (EA)和usnic acid (UA)单独或与TMZ和PTX联合研究其免疫调节和化学敏感性增加潜力。方法:用Epr (EprDCM、EprACN)、Car (CarHex、CarACN)的正己烷(Hex)、二氯甲烷(DCM)和乙腈(ACN)提取物处理抗tmz的U-87细胞、MCF7 bc细胞和正常人皮肤成纤维细胞(HSKF),并用EA和UA测定细胞代谢活性。使用ChemGPS-NP预测分子机制,并通过Western blot、RNA测序、定量RT-PCR和Wnt抑制因子1 (WIF1)蛋白表达进行验证。采用组合指数(CI)和零相互作用效价法(ZIP)计算组合效应。结果:提取物和选定的代谢物降低了U-87和MCF7细胞的浓度依赖性细胞代谢活性。EprACN和EA (U-87细胞:IC50 30 μg/mL)对HSKF安全,可调节MAP激酶通路中的关键蛋白,支持ChemGPS-NP的预测。EA-TMZ联合用药表现出累加效应(tmz减少3.4倍),减少Wnt通路成员的转录,增加U-87细胞中Wnt信号中枢抑制剂WiF1的蛋白释放。进一步的基因表达数据(GE)表明IL-17受体和BDNF参与其中。讨论:EA-TMZ联合用药与Wnt通路调控相互作用,使U-87细胞增敏,但不增加促炎细胞因子的GEs。EA作为辅助治疗值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信